Valsartan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Valsartan: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Valsartan is a widely used angiotensin II receptor blocker (ARB), whose original approved indication text is not documented in this Evidence Pack but is generally recognized as hypertension and related cardiovascular conditions. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, currently supported by 0 clinical trials and 1 preclinical publication (on a related but different drug), representing mechanism-level evidence only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this Evidence Pack (Valsartan is a well-established ARB commonly indicated for hypertension) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the drug profile itself. However, the repurposing rationale attached to this prediction indicates that valsartan acts as an AT1 (angiotensin II type 1) receptor antagonist, blocking angiotensin II–mediated vasoconstriction. This reduces systemic blood pressure and intraglomerular pressure, a mechanism with direct physiological relevance to hypertension-driven kidney injury.
Malignant hypertensive renal disease is a severe complication of uncontrolled hypertension, characterized by rapid glomerular and renal vascular damage. Extending an AT1-blocking antihypertensive agent to this indication is mechanistically plausible, since RAAS blockade is already a cornerstone strategy for slowing progression of hypertensive nephropathy in clinical practice.
That said, the supporting literature in this Evidence Pack does not involve valsartan directly — it studies avosentan, an endothelin receptor antagonist, in a rat model of hypertensive nephropathy. This provides indirect pathway-level support (RAAS/vascular injury biology) rather than valsartan-specific pharmacological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24368192 | 2014 | Preclinical (other-drug study) | Pharmacological Research | In double-transgenic rats overexpressing human renin/angiotensinogen, avosentan (an endothelin antagonist, not valsartan) was renoprotective against hypertensive nephropathy at doses that did not cause fluid retention — supporting the general RAAS/vascular injury pathway rather than valsartan-specific efficacy. |
EU Market Information
No EU marketing authorization records are present in this Evidence Pack (total_licenses = 0); the reported market status for this candidate is Not Marketed.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L4 (preclinical/mechanistic only), with no valsartan-specific clinical trials or human data for malignant hypertensive renal disease, and the only supporting publication studies a different drug (avosentan). Combined with a blocking data gap on regulatory safety labeling and no confirmed marketing authorization, the evidence base does not yet support proceeding.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (currently a Blocking data gap — DG001)
- Confirmed mechanism of action documentation for valsartan (High-severity data gap — DG002)
- Valsartan-specific preclinical or clinical data in hypertensive nephropathy/malignant hypertension models
- Drug interaction (DDI) and safety monitoring data before any S1 safety screening can be completed
- Clarification of regulatory/market status, given the “Not Marketed” flag for this jurisdiction
Note: Among the other predicted indications assessed in this pack, “chronic pulmonary heart disease” (rank 6) reached a higher evidence tier (L3) via sacubitril/valsartan combination trials, but that evidence reflects a fixed-dose combination product rather than valsartan monotherapy and would require separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.